These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 10972396)

  • 1. Deferiprone for thalassaemia.
    Kontoghiorghes GJ; Agarwal MB; Grady RW; Kolnagou A; Marx JJ
    Lancet; 2000 Jul; 356(9227):428-9. PubMed ID: 10972396
    [No Abstract]   [Full Text] [Related]  

  • 2. Iron chelators for thalassaemia.
    Hershko C; Konijn AM; Link G
    Br J Haematol; 1998 Jun; 101(3):399-406. PubMed ID: 9633877
    [No Abstract]   [Full Text] [Related]  

  • 3. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR; Martin MB
    N Engl J Med; 1998 Dec; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract]   [Full Text] [Related]  

  • 5. Deferiprone approved for iron overload.
    Traynor K
    Am J Health Syst Pharm; 2011 Nov; 68(22):2106. PubMed ID: 22058092
    [No Abstract]   [Full Text] [Related]  

  • 6. Oral deferiprone for iron chelation in people with thalassaemia.
    Roberts DJ; Brunskill SJ; Doree C; Williams S; Howard J; Hyde CJ
    Cochrane Database Syst Rev; 2007 Jul; (3):CD004839. PubMed ID: 17636775
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Iron chelation with oral deferiprone in patients with thalassemia.
    Grady RW; Giardina PJ
    N Engl J Med; 1998 Dec; 339(23):1712-3; author reply 1713-4. PubMed ID: 9867541
    [No Abstract]   [Full Text] [Related]  

  • 8. Iron chelation with oral deferiprone in patients with thalassemia.
    Wonke B; Telfer P; Hoffbrand AV
    N Engl J Med; 1998 Dec; 339(23):1712; author reply 1713-4. PubMed ID: 9867540
    [No Abstract]   [Full Text] [Related]  

  • 9. The effectiveness of deferiprone in thalassemia.
    Dogherty P; Einarson T; Koren G; Sher G
    Blood; 1997 Jul; 90(2):894. PubMed ID: 9226195
    [No Abstract]   [Full Text] [Related]  

  • 10. Iron chelation with oral deferiprone in patients with thalassemia.
    Callea F
    N Engl J Med; 1998 Dec; 339(23):1710-1; author reply 1713-4. PubMed ID: 9867537
    [No Abstract]   [Full Text] [Related]  

  • 11. Reduction of body iron stores to normal range levels in thalassaemia by using a deferiprone/deferoxamine combination and their maintenance thereafter by deferiprone monotherapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Eur J Haematol; 2010 Nov; 85(5):430-8. PubMed ID: 20662901
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of deferiprone for iron chelation in patients with transfusion-dependent thalassaemia.
    Jamuar SS; Lai AH; Tan AM; Chan MY; Tan ES; Ng IS
    J Paediatr Child Health; 2011 Nov; 47(11):812-7. PubMed ID: 21902752
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Iron chelation with oral deferiprone in patients with thalassemia.
    Tricta F; Spino M
    N Engl J Med; 1998 Dec; 339(23):1710; author reply 1713-4. PubMed ID: 9867536
    [No Abstract]   [Full Text] [Related]  

  • 14. Myocyte damage and loss of myofibers is the potential mechanism of iron overload toxicity in congestive cardiac failure in thalassemia. Complete reversal of the cardiomyopathy and normalization of iron load by deferiprone.
    Kolnagou A; Michaelides Y; Kontos C; Kyriacou K; Kontoghiorghes GJ
    Hemoglobin; 2008; 32(1-2):17-28. PubMed ID: 18274979
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Iron chelation with oral deferiprone in patients with thalassemia.
    Nathan DG; Weatherall DJ
    N Engl J Med; 1998 Dec; 339(23):1711-2; author reply 1713-4. PubMed ID: 9867538
    [No Abstract]   [Full Text] [Related]  

  • 16. Effect of deferiprone on liver iron overload and fibrosis in hepatitis-C-virus-infected thalassemia.
    Chen AC; Peng CT; Wu SF; Wu KH; Chiang IP; Tsai CH
    Hemoglobin; 2006; 30(2):209-14. PubMed ID: 16798645
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of deferiprone and deferrioxamine for the treatment of transfusional iron overload in children with beta thalassemia major.
    Waheed N; Ali S; Butt MA
    J Ayub Med Coll Abbottabad; 2014; 26(3):297-300. PubMed ID: 25671931
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deferiprone: second-line treatment of iron overload in the absence of a better alternative.
    Prescrire Int; 2007 Oct; 16(91):196. PubMed ID: 17926834
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Successful chelation therapy with the combination of deferasirox and deferiprone in a patient with thalassaemia major and persisting severe iron overload after single-agent chelation therapies.
    Voskaridou E; Christoulas D; Terpos E
    Br J Haematol; 2011 Sep; 154(5):654-6. PubMed ID: 21615376
    [No Abstract]   [Full Text] [Related]  

  • 20. Efficacy and safety of iron-chelation therapy with deferoxamine, deferiprone, and deferasirox for the treatment of iron-loaded patients with non-transfusion-dependent thalassemia syndromes.
    Kontoghiorghe CN; Kontoghiorghes GJ
    Drug Des Devel Ther; 2016; 10():465-81. PubMed ID: 26893541
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.